Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer

Creators: Buglione, Michela; Maddalo, Marta; CORVO', RENZO GIACINTO; Pirtoli, Luigi; Paiar, Fabiola; Lastrucci, Luciana; Stefanacci, Marco; BELGIOIA, LILIANA; Crociani, Monica; Vecchio, Stefania; Bonomo, Pierluigi; Bertocci, Silvia; Borghetti, Paolo; Pasinetti, Nadia; Triggiani, Luca; Costa, Loredana; Tonoli, Sandro; Grisanti, Salvatore; Magrini, Stefano Maria

Others:: Buglione, Michela; Maddalo, Marta; Corvo', RENZO GIACINTO; Pirtoli, Luigi; Paiar, Fabiola; Lastrucci, Luciana; Stefanacci, Marco; Belgioia, Liliana; Crociani, Monica; Vecchio, Stefania; Bonomo, Pierluigi; Bertocci, Silvia; Borghetti, Paolo; Pasinetti, Nadia; Triggiani, Luca; Costa, Loredana; Tonoli, Sandro; Grisanti, Salvatore; Magrini, Stefano Maria

Description

We report a subgroup analysis primarily focused on human papillomavirus (HPV)-related oropharyngeal cancer (OPC) from the Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (CTXMAB+RT; ClinicalTrials.gov identifier NCT01216020) trial comparing radiation therapy with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line treatment of locally advanced head and neck cancer.

Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer

Description

Additional details